A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

333

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma,Soft Tissue

Interventions

DRUG: INT230-6
DRUG: Eribulin
DRUG: Trabectedin
DRUG: Pazopanib

Sponsor

Intensity Therapeutics, Inc.

Collaborators

[object Object]